Evaluating patients with HTLV-I infection and tropical spastic paraparesis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate the natural history of human T-lymphotropic virus type-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) by conducting longitudinal assessments of patients diagnosed with the condition. It will monitor clinical progression and analyze virological and immunological changes over time. Eligible participants include those with confirmed HTLV-I infection, seroindeterminate individuals, and healthy volunteers. The study will involve periodic testing and evaluations to gather comprehensive data on the disease's progression.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

Participants that meet one of the following criteria:

* Test positive for HTLV infection (positive HTLV-1 ELISA followed by a positive Western blot)
* Positive HTLV ELISA but a Western Blot that only partially fulfills the above criteria (seroindeterminate)
* Have a family member/significant other who is HTLV positive, and may have been exposed to the virus
* Healthy volunteer AND
* Willingness to participate in the protocol evaluations and procedures.

EXCLUSION CRITERIA:

* Unwillingness or inability to participate in the protocol evaluations and procedures.
* The presence of any medical, social, or psychiatric conditions that in the opinion of the investigator may affect the safety of the patients or compliance with the protocol.
* Patients/healthy volunteers under the age of 18 are excluded.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Steven Jacobson, Ph.D. — National Institute of Neurological Disorders and Stroke (NINDS)
• Study coordinator: Christopher Y Itoh, M.D.
• Email: christopher.itoh@nih.gov
• Phone: (301) 496-3825

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dolutegravir with or without Tenofovir for HTLV-1 infection

  This phase 2b trial tests whether dolutegravir alone or with tenofovir can lower HTLV-1 proviral load and improve related symptoms in adults with HTLV-1 infection.

  Recruiting Phase 2 Fundação Bahiana de Infectologia · Salvador, Estado de Bahia · NCT07555431

• Combining lenalidomide with standard chemotherapy for adult T-cell leukemia-lymphoma

  This study is testing if adding lenalidomide to standard chemotherapy can help adults with T-cell leukemia-lymphoma feel better and live longer.

  Recruiting at 16 sites Phase 1 National Cancer Institute (NCI) · Atlanta, Georgia and 18 other locations · NCT04301076

• Targeting the plantaris tendon during surgery to correct ankle equinus in children

  This trial tests whether cutting the small plantaris tendon, together with standard calf-lengthening surgery, helps children aged 4–17 with ankle equinus walk and use their feet better.

  Recruiting University of Alberta · Edmonton, Alberta · NCT07090057

• Intensive training program for patients with hereditary spastic paraparesis

  This study tests if a 6-week intensive physical rehab program can help people with hereditary spastic paraparesis walk faster.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT06229626

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.